8-K current report · filed Sep 22, 2026

Lucid Diagnostics Inc. (LUCD) 8-K Current Report: September 22, 2026

Item EX-99.1Item 7.01LUCD overview

Short answer

Lucid Diagnostics Inc. (LUCD) filed an 8-K current report with the SEC on September 22, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Lucid announced payment, billing, and coding advances for EsoGuard and EsoCheck.

Lucid Diagnostics Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Lucid announced payment, billing, and coding advances for EsoGuard and EsoCheck
  • Developments followed three public meetings, potentially supporting broader reimbursement and commercial adoption
  • Exhibit 99.1 contains the detailed pathway updates and their expected implications

Item EX-99.1 · Exhibit EX-99.1

  • CMS advisory panel recommended preserving EsoGuard’s original gapfill payment basis under CLFS for PLA code 0114U
  • Final Medicare payment determination expected in November after public comment, reducing near-term reimbursement uncertainty
  • New Category III CPT code approved for EsoCheck nonendoscopic cell collection, enabling physician reporting and utilization tracking
  • Proposed ICD-10-CM code R85.83 positively received, supporting documentation for follow-up endoscopy after positive EsoGuard results
  • Texas laboratory begins Medicare claims under code 0114U this month; California claims await revised LCD after reconsideration

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Lucid Diagnostics Inc. 8-K filings

Get the next LUCD 8-K as it lands

Follow LUCD for push alerts, or ask the research agent what this filing means.